Pascal Biosciences to Present at Cannabinoid Derived Pharmaceuticals Industry Review Summit

Author's Avatar
Jan 21, 2021
Article's Main Image

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 21, 2021 / Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV:PAS, Financial)(OTC PINK:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today. Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements of Pascal's development program for treatment of glioblastoma with PAS-403. The title of his presentation is "Discovery & Development of a Cannabinoid-Derived Therapeutic for Glioblastoma".